Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE,...
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and...
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to...
Telix Refinances Convertible Bonds
MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned...
Telix at ANZSNM Annual Scientific Meeting 2025
MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of...
